USA flag logo/image

An Official Website of the United States Government

Neurogastric electrical stimulation for treating chemotherapy-induced emesis

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88846
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
CA121489
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
TRANSTIMULATION RESEARCH, INC.
921 NE 13TH ST (VRF/151) OKLAHOMA CITY, OK 73104-5007
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Neurogastric electrical stimulation for treating chemotherapy-induced emesis
Agency: HHS
Contract: 1R43CA121489-01A1
Award Amount: $100,000.00
 

Abstract:

DESCRIPTION (provided by applicant): Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. Over one million people get cancer each year. Approximately one out of every two American men and one out of every three A merican women will have some type of cancer at some point during their lifetime. Cisplatin is one of the most commonly used drugs in chemotherapy for cancers. However, severe adverse events resulting from chemotherapies, mainly nausea and vomiting may be m uch more distressing to a patient than future concerns of life expectancy. In fact, some patients choose to discontinue potentially curative therapy because of severe Cisplatin-induced nausea and vomiting. Antiemetic agents are the most common inte rvention in the management of chemotherapy-induced nausea and vomiting in cancer patients. The basis for antiemetic therapy is the neurochemical control of vomiting. However, currently, there are no satisfactory therapies for treating chemotherapy-induced emesis, especially delayed emesis. Neurogastric electrical stimulation (nGES) has recently been proposed and found effective in treating nausea and vomiting in patients with gastroparesis. Its central and neuronal mechanisms have recently been elucidated. It is hypothesized that nGES is effective in treating chemotherapy-induced emesis. The long-term aim of this project is to develop an endoscopically implantable microstimulator for the treatment of chemotherapy-induced emesis. The aim of this Phase I project is to study the feasibility of this novel method for treating chemotherapy- induced emesis. Specific objectives include a feasibility study in an animal model of Cisplatin-induced emesis, central and neuronal mechanistic studies involving nGES a nd optimization of the nGES therapy based on the mechanisms of action. A competitive team has been established, including experts in gastrointestinal electrical stimulation, physiology of the central nervous system and micro-stimulators. PUBLIC HEA LTH RELEVANCE: Chemotherapy-induced emesis is one of major problems in the treatment of patients with cancer and occurs in more than 90% of cases with certain medications, such as Cisplatin. With the recent advancement of anti-emetic medications, acute eme sis is better controlled; however, delayed emesis remains a big challenge. A novel method of neurogastric electrical stimulation (nGES) is proposed in this project for the treatment of chemotherapy-induced emesis. Preliminary data supports this novel conce pt and experiments are designed to test the feasibility of the proposed method.

Principal Investigator:

Jiande Chen
8326408111
JIANDECHEN@TRANSTIMULATION.COM

Business Contact:


jiandechen@transtimulation.com
Small Business Information at Submission:

TRANSTIMULATION RESEARCH, INC.
TRANSTIMULATION RESEARCH, INC. 921 NE 13TH ST (VRF/151) OKLAHOMA CITY, OK 73104

EIN/Tax ID: 156252394
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No